Gastric cytoprotection is secondary to increased mucosal fluid secretion: a study of six cytoprotective agents in the rat.
We tested the hypothesis that rapidly developing gastric cytoprotection produced by topical application of exogenous compounds is a result of increased gastric mucosal fluid secretion. Ex vivo gastric chambers were prepared in rats which were subsequently exposed topically to one of the prostaglandin (PG) E1 analogues misoprostol or rioprostil, PGE2, nicotine, N-ethylmaleimide (NEM), 0.25 M HCl, or to their respective vehicles. All agents were added to empty chambers to avoid complications resulting from dilution by gastric contents. Effects of these agents on intraluminal volume changes, blood flow, juxtamucosal pH, histology, and on the mucosal damage resulting from necrotizing agents were studied. All six agents were cytoprotective and each increased net secretion of fluid by the chambered mucosae. Gastric blood flow was not significantly increased by NEM, by 0.25 M HCl, or by nicotine compared to controls, and the juxtamucosal pH was not significantly increased by any of the three agents for which this was studied. Vacuole formation in surface epithelial cells and subepithelial edema were seen after exposure to some agents, but none of the agents led to formation of a thick barrier of exfoliated cells and mucus. Ablation of primary afferent nerves with capsaicin abolished both protection by 0.25 M HCl and the net increase in fluid secretion by the mucosae. Capsaicin ablation did not alter either the protection afforded by NEM or the increase in volume of secretion. We conclude that increased mucosal fluid secretion is the common factor present with all six cytoprotective agents and hence may be the predominant mechanism of cytoprotection against topically applied necrotizing agents.
Morris
G P
GP
Department of Biology, Queen's University, Kingston, Ontario, Canada.
Fallone
C A
CA
Pringle
G C
GC
MacNaughton
W K
WK
D000818:Animals; D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D002211:Capsaicin; D019610:Cytoprotection; D003603:Cytotoxins; D015232:Dinoprostone / Q000494:pharmacology*; D005033:Ethylmaleimide / Q000494:pharmacology*; D005260:Female; D005753:Gastric Mucosa / Q000098:blood supply / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D006851:Hydrochloric Acid / Q000494:pharmacology*; D008297:Male; D016595:Misoprostol / Q000494:pharmacology; D009538:Nicotine / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012039:Regional Blood Flow / Q000187:drug effects; D016630:Rioprostil / Q000494:pharmacology
D000897:Anti-Ulcer Agents; D003603:Cytotoxins; D016595:Misoprostol; D009538:Nicotine; D016630:Rioprostil; D015232:Dinoprostone; D005033:Ethylmaleimide; D006851:Hydrochloric Acid; D002211:Capsaicin